EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
4 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| propranolol EU/3/22/2713 25 clinical trials → |
Treatment of familial cerebral cavernous malformations | Active (positive) | 11 Nov 2022 |
| propranolol hydrochloride EU/3/19/2217 25 clinical trials → |
Treatment of retinopathy of prematurity | Active (positive) | 17 Oct 2019 |
| propranolol hydrochloride EU/3/17/1841 25 clinical trials → |
Treatment of von Hippel-Lindau disease | Active (positive) | 27 Feb 2017 |
| propranolol EU/3/16/1805 25 clinical trials → |
Treatment of soft tissue sarcoma | Active (positive) | 12 Dec 2016 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.